MedTrace Logo

The Utility of Ischemia Modified Albumin (IMA) in Sepsis

NCT00448968 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2007-09-27

No results posted yet for this study

Summary

The purpose of this study is to determine if levels of ischemia modified albumin (IMA) in blood are elevated in patients with suspected infection and are predictive of severity of illness in patients with sepsis.

In order to compare subjects with infection to those without infection who are representative of the ED population at each site, a group of non-infected control patients will be enrolled. Each hospital will enroll subjects with age (by decade) and sex matched controls to reflect the population of subjects suspected of infection.

Conditions

  • Sepsis
  • Severe Sepsis
  • Systemic Inflammatory Response Syndrome
  • Sepsis Syndrome

Sponsors & Collaborators

  • Inverness Medical Innovations

    lead INDUSTRY

Principal Investigators

  • Nathan Shapiro, M.D. · Beth Israel Deaconess Medical Center

  • Munish Goyal, M.D. · University of Pennsylvania

  • Rakesh Engineer, M.D. · The Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448968 on ClinicalTrials.gov